Evidence map›Paper›PMID 31168213›Full record

ArticleActa clinica Croatica2018

THE ROLE OF E2/P RATIO IN THE ETIOLOGY OF FIBROCYSTIC BREAST DISEASE, MASTALGIA AND MASTODYNIA.

Milena Brkić, Svetlana Vujović, Miomira Ivović, Milina Tančić Gajić, Ljiljana Marina, Maja Franić Ivanišević, Damir Franić

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Acta clinica Croatica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Milena Brkić1Medical Faculty, University of Banja Luka, Banja Luka, Bosnia and Herzegovina; 2Department of Endocrinology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia; 3Department of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade, Serbia; 4Outpatient Clinic of Obstetrics and Gynecology, Rogaška Slatina, Slovenia; 5School of Medicine, University of Maribor, Maribor, Slovenia.
Svetlana Vujović1Medical Faculty, University of Banja Luka, Banja Luka, Bosnia and Herzegovina; 2Department of Endocrinology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia; 3Department of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade, Serbia; 4Outpatient Clinic of Obstetrics and Gynecology, Rogaška Slatina, Slovenia; 5School of Medicine, University of Maribor, Maribor, Slovenia.
Miomira Ivović1Medical Faculty, University of Banja Luka, Banja Luka, Bosnia and Herzegovina; 2Department of Endocrinology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia; 3Department of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade, Serbia; 4Outpatient Clinic of Obstetrics and Gynecology, Rogaška Slatina, Slovenia; 5School of Medicine, University of Maribor, Maribor, Slovenia.
Milina Tančić Gajić1Medical Faculty, University of Banja Luka, Banja Luka, Bosnia and Herzegovina; 2Department of Endocrinology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia; 3Department of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade, Serbia; 4Outpatient Clinic of Obstetrics and Gynecology, Rogaška Slatina, Slovenia; 5School of Medicine, University of Maribor, Maribor, Slovenia.
Ljiljana Marina1Medical Faculty, University of Banja Luka, Banja Luka, Bosnia and Herzegovina; 2Department of Endocrinology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia; 3Department of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade, Serbia; 4Outpatient Clinic of Obstetrics and Gynecology, Rogaška Slatina, Slovenia; 5School of Medicine, University of Maribor, Maribor, Slovenia.
Maja Franić Ivanišević1Medical Faculty, University of Banja Luka, Banja Luka, Bosnia and Herzegovina; 2Department of Endocrinology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia; 3Department of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade, Serbia; 4Outpatient Clinic of Obstetrics and Gynecology, Rogaška Slatina, Slovenia; 5School of Medicine, University of Maribor, Maribor, Slovenia.
Damir Franić1Medical Faculty, University of Banja Luka, Banja Luka, Bosnia and Herzegovina; 2Department of Endocrinology, Clinical Center of Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia; 3Department of Gynecology and Obstetrics, Clinical Center of Serbia, Belgrade, Serbia; 4Outpatient Clinic of Obstetrics and Gynecology, Rogaška Slatina, Slovenia; 5School of Medicine, University of Maribor, Maribor, Slovenia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

- The aim of the study was to assess the role of the estradiol and progesterone relationship during the late luteal phase and the occurrence of fibrocystic breast disease (FBD). The concentration of estradiol/progesterone was measured in the group of women with FBD as study group (n=50) and control group of women without FBD (n=40). All women had regular ovulation cycles. Blood samples for estradiol (E2), progesterone (P) and prolactin determination were obtained in the morning at 8 am on days 21 and 24 of menstrual cycle. Significant mastalgia and mastodynia history in women with FBD was obtained with yes or no questionnaire. FBD diagnosis was confirmed with ultrasound (size and number of simple cysts). In the control group, a reduced E2/P ratio was noticed from day 21 to day 24 of the cycle (from 14.8±11.5 pg/mL to 9.1±6.1 pg/mL; p<0.05), which was not recorded in the group of women with FBD (study group). Even the slightest disturbance of the E2/P ratio may contribute to the occurrence of FBD with clinical manifestations of mastalgia and mastodynia.

Indexed as

Fibrocystic Breast DiseaseAdultCorrelation of DataEstradiolFemaleHumansLuteal PhaseMastodyniaPain MeasurementProgesteroneProlactinUltrasonography, MammaryEstradiolProgesteroneProlactinEstradiolFibrocystic breast diseaseLuteal phaseProgesterone

Identifiers

PMID31168213
PMCPMC6544108

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.